Sector News

Sanofi sacks chief executive Viehbacher

October 29, 2014
Life sciences
Sanofi’s Board of Directors has sacked chief executive Chris Viehbacher abruptly cutting his six-year run at the helm of the firm.
 
The French drugmaker said in a rather terse statement this morning that the Board had “unanimously” agreed to “remove” Viebacher, but also thanked him for “all the work done during the last six years, which has enabled the Group to move through a sensitive and important transition phase”. 
 
The rumour mill has been running for some time over Viehbacher’s future at the firm, largely because of his tough management style, relocation to the US this year, and recent run in with chairman Serge Weinberg. French newspaper Les Echos published last week a letter dated September 4 in which Viehbacher said he had become aware that Weinberg was “actively seeking a successor”.
 
“Changing the CEO would be against a backdrop of a company and a leader perceived to be succeeding strongly. Such a change would be difficult to understand”, he wrote, making his case to stay in the role.
 
Disagreement and poor cooperation
Weinberg reportedly said the decision to sack him was made because of disagreement over the chief executive’s management style and poor cooperation with the board, according to Reuters, and he also told a press conference that there was “a lack of trust in Viehbacher’s relationship with the board”.
 
In a statement, the Board said Sanofi “needs to pursue its development with a management aligning the teams, harnessing talents and focusing on execution with a close and confident cooperation with the board”.
 
None-the-less, it is quite shocking that the firm made the move without having a replacement lined up. For now, Weinberg will assume the role temporarily.
 
The news, coupled with yesterday’s that diabetes sales at the firm could be flat next year, saw almost 17 billion euros wiped from its value this week, according to reports.
 
By Selina McKee
 
 

comments closed

Related News

October 17, 2021

Colorcon acquires a majority share in Ideal Cures Pvt. Ltd., India

Life sciences

Ideal Cures will operate as a fully independent entity within Colorcon. Their business complements Colorcon’s position in the Indian pharmaceutical market with a strong presence in the domestic generic sector comprised of long-standing customer relationships sustained by innovative and customized solutions.

October 17, 2021

Barriers exist, but participation urgent in breast cancer clinical trials: report

Life sciences

Across four new breast cancer treatments approved by the FDA last year, 2% to 9% of patients in clinical trials for the drugs were Black Americans and 0% to 9% were Hispanic, according to a new report from Breastcancer.org.

October 17, 2021

Danish consortium acquires part of Jernbanebyen to create one of the world’s healthiest urban villages

Life sciences

The southern section of Jernbanebyen in central Copenhagen has a new owner. The Baneby Consortium, comprising NREP, Novo Holdings and Industriens Pension, has bought the land from Freja Ejendomme. The ambition is to create a green, partly car-free environment that will also be one of the healthiest in the world. 

Send this to a friend